IL23A and inflammatory bowel disease: Since its discovery, targeting IL-23 has been an area of significant research interest when developing new treatments for IMIDs, and ustekinumab, a monoclonal antibody that inhibits both IL-12 and IL-23, has been shown to be effective in several IMIDs, including IBD [6,7,8,9].